

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	☒ None	Entity Type
0001401914	Cerulean Pharma Inc.		☒ Corporation
Name of Issuer	Tempo Pharmaceuticals Inc		☐ Limited Partnership
Dare Bioscience, Inc.			☐ Limited Liability Company
Jurisdiction of Incorporation/Organization			☐ General Partnership
DELAWARE			☐ Business Trust
Year of Incorporation/Organization			☐ Other (Specify)
☒ Over Five Years Ago			
☐ Within Last Five Years (Specify Year)			
☐ Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name of Issuer			
Dare Bioscience, Inc.			
Street Address 1	Street Address 2		
3655 NOBEL DRIVE	SUITE 260		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92122	858-926-7655

3. Related Persons

Last Name	First Name	Middle Name
Johnson	Sabrina	Martucci
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122
Relationship:	☒ Executive Officer	☒ Director
	☐ Promoter	

Clarification of Response (if Necessary):

[President and Chief Executive Officer](#)

Last Name	First Name	Middle Name
Haring-Layton	MarDee	
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122
Relationship:	☒ Executive Officer	☐ Director
	☐ Promoter	

Clarification of Response (if Necessary):

[Chief Accounting Officer](#)

Last Name	First Name	Middle Name
Rastetter	William	H.
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122

Relationship: ☐ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Grossman	Jessica	D.
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Kelley	Susan	L.
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Matz	Gregory	W.
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Steele	Robin	J.
Street Address 1	Street Address 2	
3655 Nobel Drive	Suite 260	
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92122
Relationship: ☐ Executive Officer ☒ Director ☐ Promoter		

Clarification of Response (if Necessary):

4. Industry Group

☐ Agriculture	Health Care	☐ Retailing
Banking & Financial Services	☒ Biotechnology	☐ Restaurants
☐ Commercial Banking	☐ Health Insurance	Technology
☐ Insurance	☐ Hospitals & Physicians	☐ Computers
☐ Investing	☐ Pharmaceuticals	☐ Telecommunications
☐ Investment Banking	☐ Other Health Care	☐ Other Technology
☐ Pooled Investment Fund	☐ Manufacturing	Travel
Is the issuer registered as an investment company under the Investment Company Act of 1940?	Real Estate	☐ Airlines & Airports
☐ Yes ☐ No	☐ Commercial	☐ Lodging & Conventions
☐ Other Banking & Financial Services	☐ Construction	☐ Tourism & Travel Services
☐ Business Services	☐ REITS & Finance	☐ Other Travel
Energy	☐ Residential	☐ Other
☐ Coal Mining	☐ Other Real Estate	
☐ Electric Utilities		
☐		

- ☐ Energy Conservation
- ☐ Environmental Services
- ☐ Oil & Gas
- ☐ Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
☐ No Revenues		☐ No Aggregate Net Asset Value
☐ \$1 - \$1,000,000		☐ \$1 - \$5,000,000
☐ \$1,000,001 - \$5,000,000		☐ \$5,000,001 - \$25,000,000
☐ \$5,000,001 - \$25,000,000		☐ \$25,000,001 - \$50,000,000
☐ \$25,000,001 - \$100,000,000		☐ \$50,000,001 - \$100,000,000
☐ Over \$100,000,000		☐ Over \$100,000,000
☒ Decline to Disclose		☐ Decline to Disclose
☐ Not Applicable		☐ Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

☐ Rule 504(b)(1) (not (i), (ii) or (iii))	☐ Investment Company Act Section 3(c)	
☐ Rule 504 (b)(1)(i)	☐ Section 3(c)(1)	☐ Section 3(c)(9)
☐ Rule 504 (b)(1)(ii)	☐ Section 3(c)(2)	☐ Section 3(c)(10)
☐ Rule 504 (b)(1)(iii)	☐ Section 3(c)(3)	☐ Section 3(c)(11)
☒ Rule 506(b)	☐ Section 3(c)(4)	☐ Section 3(c)(12)
☐ Rule 506(c)	☐ Section 3(c)(5)	☐ Section 3(c)(13)
☐ Securities Act Section 4(a)(5)	☐ Section 3(c)(6)	☐ Section 3(c)(14)
	☐ Section 3(c)(7)	

7. Type of Filing

☒ New Notice Date of First Sale [2026-08-17](#) ☐ First Sale Yet to Occur

☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? ☐ Yes ☒ No

9. Type(s) of Securities Offered (select all that apply)

☐ Equity	☐ Pooled Investment Fund Interests
☐ Debt	☐ Tenant-in-Common Securities
☒ Option, Warrant or Other Right to Acquire Another Security	☐ Mineral Property Securities
☒ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	☐ Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☒ No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number ☐ None
Ladenburg Thalmann & Co. Inc.	000000505
(Associated) Broker or Dealer ☐ None	(Associated) Broker or Dealer CRD Number ☐ None
Ladenburg Thalmann & Co. Inc.	000000505
Street Address 1	Street Address 2
640 Fifth Avenue, 4th Floor	

City
New York

State/Province/Country
NEW YORK

ZIP/Postal Code
10019

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

☒ All States

☐ Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount\$12,375,054 USD or☐ Indefinite

Total Amount Sold\$12,375,054 USD

Total Remaining to be Sold\$0 USD or☐ Indefinite

Clarification of Response (if Necessary):

The total offering amount reflects proceeds if all warrants, consisting of 8,759,162 and 175,183 shares of common stock exercisable at \$1.37 and \$2.1235 per share, respectively, are exercised for cash. No warrants have been exercised as of this filing.

14. Investors

☐ Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

12

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions\$0 USD☐ Estimate

Finders' Fees\$0 USD☐ Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD☐ Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

•

Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

•

Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

•

Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Dare Bioscience, Inc.	/s/ MarDee Haring-Layton	MarDee Haring-Layton	Chief Accounting Officer	2026-08-19

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
